Good Morning NAW Subscribers,
Thanks for reading this issue of National Accounts Weekly!
Are you signed up for The Journal of Healthcare Contracting and ANAE's 2 virtual events yet? Check out the agendas and register below. You don't want to miss out on this opportunity to hear from your customers.
Tickets, which typically cost over $1,000, are under $300 this year!
CSC Summit November 9-10
IDN Summit December 9-11
John Pritchard
President of ANAE
Publisher of The Journal of Healthcare Contracting
|
|
|
|
Intermountain Healthcare plans to merge with Dakota-based Sanford Health |
Utah’s largest hospital system, Intermountain Healthcare, is planning to merge with its counterpart in the Dakotas, Sanford Health, leaders of the two companies announced Monday.
The two companies, if the merger succeeds, would have a combined workforce of 89,000 people, operating 70 hospitals, many of them in rural areas, according to Intermountain.
The two companies also operate 435 clinics in seven states, provide senior care in 233 locations in 24 states, and provide insurance to 11 million people.
The boards of the two nonprofit companies each approved a resolution to move forward on a merger. Now begins a process to perform due diligence which should take about nine months of regulatory filings and planning.
|
|
States will need billions to distribute the Covid vaccine as federal funding falls short |
Public health departments across the U.S. are preparing to distribute a coronavirus vaccine by the CDC’s Nov. 1 deadline despite questions about how the plans will be funded.
National associations representing health departments have asked Congress for more than $8 billion toward distributing the vaccine. Of that amount, the groups said, $1.2 billion will be needed for cold supply chain management, $1 billion for arranging additional vaccination sites and $500 million for data information system upgrades, among other costs.
|
|
|
|
|
Anthem to pay $594M share in pending Blues plan antitrust settlement |
Anthem is paying a substantial portion of Blues plans' tentative antitrust settlement, which is estimated to be nearly $3 billion, executives said on a call with investors on Wednesday morning.
Anthem has penciled in $594 million for its contribution to the $2.7 billion settlement. The Blue Cross and Blue Shield Association reportedly agreed to the settlement in a lengthy class action suit late last month.
In the suit, filed in 2012, Blues plans were accused of conspiring to split up geographic regions to avoid competing against one another directly. That lack of competition drove up costs, the plaintiffs allege.
|
|
“What Supply Chain Needs to Know This Respiratory Season” podcast series |
This podcast features strategies on how supply chain can help clinicians develop a vaccine strategy.
Preventing respiratory illnesses through vaccination will be critical. But, given the fear around COVID-19, how do clinicians get patients to come in for their vaccinations? And for this audience in particular, how can supply chain support their health system in creating a holistic strategy around vaccination?
|
|
|
|
|
Tenet Reports Third Quarter 2020 Results and Provides Update on Effects of COVID-19 |
Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended September 30, 2020 (3Q20).
Ronald A. Rittenmeyer, Executive Chairman and Chief Executive Officer, stated, “The third quarter of 2020 was in many ways more challenging than the second, with COVID positive inpatient census surging by approximately 64 percent in our markets in late July and August."
Net loss from continuing operations attributable to common shareholders in 3Q20 of $197 million (which included an after-tax loss of $237 million associated with early retirement of debt transactions) versus a net loss from continuing operations of $227 million in 3Q19 (which included an after-tax loss of $178 million associated with early retirement of debt transactions).
|
|
Community Health Systems, Inc. announces new CEO |
Community Health Systems, Inc. (CHS) announced that Wayne T. Smith, the company’s chairman and CEO, will transition from CEO to executive chairman of the board of directors, effective January 1, 2021.
Smith will retain certain strategic and other executive management responsibilities with regard to the future direction of the company, CHS said.
The company plans to appoint Tim L. Hingtgen as its CEO, effective January 1, 2021. Hingtgen has served as president and COO since 2016 and as a member of the company’s board of directors since 2017.
|
|
|
|
|
Supply chains may become more local as a result of the pandemic |
Drug supply chains may become less global as a result of the pandemic, according to the chief executive of a pharmaceutical manufacturer.
Martin Meeson, CEO of Fujifilm Diosynth Biotechnologies, emphasized the need for collaboration between parties involved in the production of drugs, such as universities “doing the discovery work” and manufacturers who can produce medicine at scale.
In August, the U.K. government signed a deal with Novavax to buy 60 million doses of a potential COVID vaccine, known as NVX-CoV2373, which is currently undergoing clinical trials.
The U.S. government agreed to pay Novavax $1.6 billion to develop and manufacture the vaccine in July, as part of its Operation Warp Speed initiative.
|
|
John Pritchard
Publisher of National Accounts Weekly
Please forward this to your friends and colleagues!
They can receive their own, FREE subscription to National Accounts Weekly by clicking here.
|
|
|
|
|
|
|
